A new way to
guide patient care

Definitive answers to guide better treatment

When it comes to Alzheimer’s disease, early detection is essential to better care. While Alzheimer’s is challenging to treat, early diagnosis offers a number of advantages, including access to medication and therapies used to alleviate symptoms.

Mayo Clinic Laboratories has developed two innovative evaluations for Alzheimer's disease, which use cerebrospinal fluid (CSF) biomarkers to achieve a high concordance with amyloid positron emission tomography (PET) scan. The methodology on both tests is optimized to reduce pre-analytical variability and ensure diagnostic accuracy with each result.

These clinically validated tests deliver fast results and provide new hope for correctly diagnosing and managing Alzheimer’s disease along with other dementias.

Answers for
patients and providers

Diagnosing Alzheimer’s disease is a challenge. We use the most up-to-date methodology: automated immunoassay with innovative instrumentation. Our results are based on ratios of p-tau and AB42 (ADEVL) and AB42 and AB40 (AMYR), which allows for greater than 90% diagnostic accuracy compared to standard assessments. We also use low-binding tubes, resulting in fewer false results for patients.

Clear results that guide treatment decisions

A diagnosis of Alzheimer’s disease can change patients' lives. Receiving a fast, definitive answer from a health care institution they trust can provide hope and a plan for their future. Whether it is the right treatment for symptom management, confirmation of diagnosis, or eligibility for clinical trials, we are here to provide the highest quality of care. 

Fast, cost-effective answers when you need them most

A differential diagnosis can change treatment and improve patient care. With our testing, a patient receives the answers they need in as little as one day. They don’t have to wait weeks or months to be placed on the right treatment and start planning for their future.

A complementary solution to assist with diagnosis

Standard assessment of suspected Alzheimer's disease patients through clinical and cognitive assessment is 70%–80% accurate. By adding our Alzheimer's disease evaluations, physicians can increase diagnostic accuracy by 12%–22% to ensure they are providing the correct diagnosis and treatment for patients.

Key testing

AMYR | Beta-Amyloid Ratio (1-42/1-40), Spinal Fluid

*Note: Only order in patients 55 years and older.


  • Uses the most up-to-date methodology (automated immunoassay).
  • Evaluates multiple biomarkers and ratios.
  • Aligns with consensus research diagnostic criteria for Alzheimer’s disease, mild cognitive impairment (MCI), and preclinical Alzheimer’s disease as proposed by the National Institute on Aging and Alzheimer’s Associate Research Framework.2

When to consider testing

  • For the differential diagnosis of Alzheimer’s disease versus other causes of cognitive impairment.
  • When patients present with atypical dementia symptoms.
  • To assess Alzheimer’s disease pathology in a mixed diagnosis.
  • To allow for eligibility into clinical trials.

Confirm neuronal damage

For patients suspected of having Alzheimer’s disease, testing for neurofilament light chain (NfL), a generic marker of neurodegeneration,  can confirm a neurodegenerative disease process. Mayo Clinic Laboratories has developed an innovative assay to test for elevated levels of NfL in the blood. Positive test results not only confirm neuronal damage but can offer insights on disease progression and prognosis to guide therapeutic decision-making.

Alzheimer’s Disease Evaluation

Alicia Algeciras-Schimnich, Ph.D., gives an overview of this test. She discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.

Learn more about how to order this evaluation at your institution.

Additional resources


  1. https://www.alz.org/alzheimers-dementia/facts-figures.
  2. Knopman DS, Haeberlein SB, Carrillo MC, et al. The National Institute on Aging and Alzheimer’s Association Research Framework for Alzheimer’s disease: Perspectives from the Research Roundtable. Alzheimers Dement. 2018 Apr;14(4):563-575.
  3. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019 Apr 2;321(13):1286-1294.